[go: up one dir, main page]

KR950701518A - 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease) - Google Patents

알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)

Info

Publication number
KR950701518A
KR950701518A KR1019940704236A KR19940704236A KR950701518A KR 950701518 A KR950701518 A KR 950701518A KR 1019940704236 A KR1019940704236 A KR 1019940704236A KR 19940704236 A KR19940704236 A KR 19940704236A KR 950701518 A KR950701518 A KR 950701518A
Authority
KR
South Korea
Prior art keywords
acid
fluoroallylamine
fluorophenethyl
pharmaceutically acceptable
effective amount
Prior art date
Application number
KR1019940704236A
Other languages
English (en)
Inventor
에이. 맥도날드 이안
지. 팔프레이만 마이클
Original Assignee
스티븐 엘. 네스비트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 엘. 네스비트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 스티븐 엘. 네스비트
Publication of KR950701518A publication Critical patent/KR950701518A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 알쯔하이머 질환의 치료를 필요로 하는 환자에게 치료학적 유효량의 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 염을 투여함을 포함하며, 상기 환자에게 알쯔하이머 질환을 치료하는 방법에 관한 것이다.

Description

알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-)p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 치료학적 유효량의 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산 부가염을 알쯔하이머 질환의 치료를 필요로 하는 환자에게 투여함을 포함하며, 상기 환자에게 알쯔하이머 질환을 치료하는 방법.
  2. 제1항에 있어서, 화합물이 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 염산인 방법.
  3. 제1항에 있어서, (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염의 치료학적 유효량이 1일 약0.001㎎/㎏내지 약 1.0㎎/㎏인 방법.
  4. 제1항에 있어서, 약제학적으로 허용되는 산 부가염이 염산, 브롬화수소산, 설폰산, 황산, 인산, 질산, 말레산, 푸마르산, 벤조산, 아스코르브산, 팔모산, 석신산, 메탄설폰산, 아세트산, 프로피온산, 타르타르산, 시트르산, 락트산, 말산, 마델산, 신남산, 말미트산, 스타콘산 및 벤젠설폰산으로 이루어진 그룹으로부터 선택되는 방법.
  5. 제3항에 있어서, (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염의 치료학적 유효량이 1일 약0.001㎎/㎏내지 약 0.25㎎/㎏인 방법.
  6. 제1항에 있어서, 치료학적 유효량의 E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염을 경구, 피하, 근육내, 정맥내, 경피, 비내, 직장 또는 국소 투여하는 방법.
  7. 제6항에 있어서, 치료학적 유효량의 E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염을 경구 투여하는 방법.
  8. 제6항에 있어서, 치료학적 유효량의 E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염을 경피 투여하는 방법.
  9. 알쯔하이머 질환에 걸린 환자 치료용 약제를 제조하는데 있어서의, 치료학적 유효량의 E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 또는 약제학적으로 허용되는 이의 산부가염의 용도.
  10. 알쯔하이머 질환에 걸린 환자 치료용 약제를 제조하는데 있어서의, 치료학적 유효량의 E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민 염산의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940704236A 1992-05-27 1993-04-14 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease) KR950701518A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88867192A 1992-05-27 1992-05-27
US07/888,671 1992-05-27
PCT/US1993/003522 WO1993024120A1 (en) 1992-05-27 1993-04-14 USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
KR950701518A true KR950701518A (ko) 1995-04-28

Family

ID=25393634

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704236A KR950701518A (ko) 1992-05-27 1993-04-14 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)

Country Status (15)

Country Link
EP (1) EP0642338B1 (ko)
JP (1) JPH07507299A (ko)
KR (1) KR950701518A (ko)
AT (1) ATE147978T1 (ko)
AU (1) AU672401B2 (ko)
CA (1) CA2135752C (ko)
DE (1) DE69307702T2 (ko)
DK (1) DK0642338T3 (ko)
ES (1) ES2101311T3 (ko)
GR (1) GR3022608T3 (ko)
HU (1) HUT72316A (ko)
MX (1) MX9303074A (ko)
NO (1) NO944524L (ko)
WO (1) WO1993024120A1 (ko)
ZA (1) ZA933567B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172605A1 (en) * 1993-09-24 1995-03-30 Ian A. Mcdonald Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease
US5488188A (en) * 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
US5599986A (en) * 1994-09-29 1997-02-04 Hoechst Marion Roussel Inc. Process for the preparation of alkali metal salts of diformylamide
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR243493A1 (es) * 1987-06-16 1993-08-31 Merrell Dow Pharma Procedimiento para preparar (e)-2-(p-fluorfenetil)-3-fluoralilamina y sus sales farmaceuticamente aceptables, util como inhibidor de mao-b irreversible y activado por enzimas.

Also Published As

Publication number Publication date
EP0642338B1 (en) 1997-01-22
ATE147978T1 (de) 1997-02-15
CA2135752C (en) 1998-07-14
HUT72316A (en) 1996-04-29
NO944524D0 (no) 1994-11-25
WO1993024120A1 (en) 1993-12-09
DE69307702D1 (de) 1997-03-06
DE69307702T2 (de) 1997-05-28
NO944524L (no) 1994-11-25
HU9403384D0 (en) 1995-02-28
AU672401B2 (en) 1996-10-03
EP0642338A1 (en) 1995-03-15
MX9303074A (es) 1994-01-31
GR3022608T3 (en) 1997-05-31
ES2101311T3 (es) 1997-07-01
JPH07507299A (ja) 1995-08-10
DK0642338T3 (da) 1997-02-10
ZA933567B (en) 1993-12-13
AU3978293A (en) 1993-12-30
CA2135752A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
IL208184A0 (en) Glp-1, and methods for treating diabetes
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
Hay et al. Short course ketoconazole therapy in pityriasis versicolor
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
KR950701518A (ko) 알쯔하이머 질환의 치료에 있어서 (E)-2-(p-플로오로펜에틸)-3-플루오로알릴아민의 용도(Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatmet of Alzheimer's disease)
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
NO933091L (no) Anvendelse av 1-aryl-3-(4-piperidyl)-indolderivater ved behandling av kognitive forstyrrelser
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
RU95112520A (ru) Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза
KR960705791A (ko) 기억력 향상제로서 유용한 3-아릴-4-알킬 및 4,5-디알킬-4H-1,2,4-트리아졸(3Aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles useful as memory enhancers)
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
Zimmermann et al. Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain
SK2802002A3 (en) The use of dexrazoxane, an article comprising dexrazoxane, method for treating psoriasis and method for producing a drug
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19941125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991220

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000308

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I